|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00990873 |
|
Date of registration:
|
06/10/2009 |
|
Primary sponsor: |
|
|
Public title:
|
Study of Tissue Samples From Patients With Stage I Non-Small Cell Lung Cancer Enrolled on Research Study CALGB-140202
|
|
Scientific title:
|
A Validation of the 64-Gene Signature Using Affymetrix-HG_U133A Array in Stage I NSCLC From the CALGB Lung Cancer Study (140202) |
|
Date of first enrolment:
|
July 2009 |
|
Target sample size:
|
300 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00990873 |
|
Study type:
|
Observational |
|
Study design:
|
N/A
|
|
|
Contacts
|
|
Name:
|
Ming You, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Washington University Siteman Cancer Center |
| | |
|
Key inclusion & exclusion criteria
|
DISEASE CHARACTERISTICS:
- Diagnosis of stage I non-small cell lung cancer
- Enrolled in tissue repository CALGB 140202
PATIENT CHARACTERISTICS:
- Caucasian race
PRIOR CONCURRENT THERAPY:
- Not specified
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Lung Cancer
|
|
Intervention(s)
|
|
Genetic: gene expression analysis
|
|
Genetic: microarray analysis
|
|
Genetic: reverse transcriptase-polymerase chain reaction
|
|
Other: laboratory biomarker analysis
|
|
Primary Outcome(s)
|
|
Overall survival, defined as the time from surgery to death of any cause
[Time Frame: No]
|
|
Secondary Outcome(s)
|
|
Disease-free survival, defined as time from surgery to any recurrence (local or regional), second primary tumor, distant metastasis, or death of any cause
[Time Frame: No]
|
|
Secondary ID(s)
|
|
CALGB-150803
|
|
CDR0000649826
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|